SEC Form 4 · accession 0001209191-19-014980
Vanda Pharmaceuticals Inc. · VNDA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gian Piero Reverberi
Officer — SVP & Chief Commercial Officer
Period of report
Feb 27, 2019
Accepted (ET)
Mar 1, 2019 · 4:25 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001347178
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 27, 2019 | A | 30,000 | — | A | 168,870 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F2 | $20.62 | Feb 27, 2019 | A | 70,000 | A | — | Feb 26, 2029 | Common Stock | 70,000 | 70,000 | D |
Explanation of responses
- F1Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2020, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest.
- F2The option vests in forty-eight (48) equal monthly installments from the date of grant, provided the Reporting Person remains continuously employed by the Issuer through each vesting date.